Prognostic value of p53 in non-small cell lung cancer: Relationship with proliferating cell nuclear antigen and cigarette smoking

Human Pathology

Volumn 28, Issue 2, 1997, Pages 233-237

  Esposito, Vincenzo ^b   Baldi, Alfonso ^b   De Luca, Antonio ^b   Micheli, Pietro ^b   Mazzarella, Gennaro ^b   Baldi, Feliciano ^b   Caputi, Mario ^b   Giordano, Antonio ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

NSCLC; p53; PCNA; tobacco; tumor suppressor gene

Indexed keywords

CYCLINE; PROTEIN P53;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

EID: 0031016148     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90112-X     Document Type: Article

References (29)

1. Richardson GE, Johnson BE: The biology of lung cancer. Semin Oncol 20:105-127, 1993
2. Sang N, Baldi A, Giordano A; The roles of the tumor soppressors pRb and p53 in cell proliferation and cancer. Mol Cell Differ 3:1-29, 1995
3. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
4. Finlay CA: Normal e malignant growth control by p53, in Benz CC, Liu ET (eds): Oncogenes and Tumour Suppressor Gene in Human Malignancies. Boston, Kluwer Academic, 1993, pp 327-344
5. Levine AJ: The tumor suppressor genes. Annu Rev Biochem 62:623-651, 1993
6. Korkolopoulou P, Oates J, Crocker J, et al: p53 expression in oat and non oat small cell lung carcinomas: Correlation with proliferating cell nuclear antigen. J Clin Pathol 46:1093-1096, 1993
7. Rodriguez NR, Rowan A, Smith MEF, et al: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555-7559, 1990
8. Iggo R, Gatter K, Bartek J, et al: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990
9. Navone NM, Troncoso P, Pisters LL, et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1659, 1993
10. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
11. Horio Y, Takahashi T, Kuroishi T, et al: Prognostic significance of p53 mutations and 3p deletions in primary resected non small-cell lung cancer. Cancer Res 53:1-4, 1993
12. McLaren R, Kuzu I, Dunnill M, et al: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738, 1992
13. Passlick B, Izbicki JR, Haussinger K, et al: Immunohistochemical detection of p53 protein is not associated with poor prognosis in non small cell lung cancer. J Thorac Cardiovasc Surg 109:1205-1211, 1995
14. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
15. Top B, Mooi WJ, Klaver SG, et al: Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 64:83-91, 1995
16. Volm M, Mattern J: Immunohistochemical detection of p53 in non small cell lung cancer. J Natl Cancer Inst 86:801-802, 1994
17. Fontanini G, Macchiarini P, Pepe S, et al: The expression of proliferation cell nuclear antigen in paraffin sections of periferal, node negative, NSCLC. Cancer 70:1520-1527, 1992
18. Hall PA, Levinson DA, Woods AL, et al: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with the evidence of deregulated expression in some neoplasms. J Pathol 162:285-294, 1990
19. Shopland DR, Eyre HJ, Pechacek TF: Smoking attributable cancer mortality in 1991: Is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 83:1142-1148, 1991
20. World Health Organization: Histological Typing of Lung Tumors (ed 2). Geneva, 1981, pp 25-26
21. Beahrs OH, Henson DE, Hutter RVP, et al: Lung, in Manual for Staging of Cancer (ed 4). Chicago, IL, American Joint Committee on Cancer, 1992, pp 115-122
22. Dosaka-Akita H, Shindoh M, Fujino M, et al: Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol 102:660-664, 1994
23. Ebina M, Steimberg SM, Mulshine JL, et al: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non small cell lung cancer. Cancer Res 54:2496-2503, 1994
24. Ramael M, Jacobs W, WejlerJ, et al: Proliferation in malignant mesothelioma determined by mitosis count and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathol 172:247-253, 1994
25. Shonborn I, Zschiesche W, Minguillon C, et al: Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer. J Cancer Res Clin Oncol 121:115-122, 1995
26. Mercer WE, Shields MT, Lin D, et al: Growth suppression induced by wild type p53 protein is accompanied by selective down regulation of proliferation cell nuclear antigen expression. Proc Natl Acad Sci U S A 88:1958-1962, 1991
27. Deb S, Jackson CT, Subler MA, et al: Modulation of cellular and viral promotors by mutant human p53 proteins was found in tumor cells. J Virol 66:6164-6170, 1994
28. Puisieux A, Lim S, Groopman J, et al: Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 51:6185-6189, 1991
29. Suzuki H, Takahashi T, Kuroishi T, et al: p53 mutations in non small cell lung cancer in Japan: Association beetween mutations and smoking. Cancer Res 52:734-736, 1992